Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

921 - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience


24 Nov 2018


Poster display - Cocktail


Tumour Site

Breast Cancer


Junichiro Watanabe


Annals of Oncology (2018) 29 (suppl_9): ix13-ix20. 10.1093/annonc/mdy428


J. Watanabe, S. Nakamoto

Author affiliations

  • Breast Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP

Abstract 921


Eribulin mesylate (ERI) exerts anticancer activity in both early- and late-line settings in the management of ER+HER2- metastatic breast cancer (MBC) patients; however, the utility of rechallenge or a second administration of ERI has not been well discussed.


The outcomes of ER+HER2-MBC patients who received ERI therapy at our institute from November 2011 to the present were reviewed. Statistical analyses were performed using the Kaplan-Meyer method and Spearman's rank correlation coefficient.


We identified 90 ER+HER2-MBC patients who had terminated their first-line of ERI therapy (1stERI), with a median time-to-treatment failure (TTF) of 134.0 days (95% confidence interval [CI]115.6-152.4), and 22 of 90 (24.4%) underwent a 2ndERI. Of these 22 patients, the TTF was significantly better than at the 1stERI compared with patients who did not undergo 2ndERI (median 181.0 days vs. 119.0 days; P < 0.01). Patients received a median of 2 (range 1-5) regimens between the 1st- and 2nd- ERI, and the median number of regimens patients received prior to 2ndERI was 4 (range 2-10). A majority (16/22, 72.7%) received chemotherapy prior to the 2ndERI. The median TTF of prior systemic therapy was 141.0 days (95% CI 70.9-211.1), and the major cause of discontinuation was progression of known lesions (19/22, 86.4%). The median TTF of the 2ndERI was 97.0 days (95% CI 82.2-111.8), and causes of discontinuation (excluding 1 patient still on treatment) were as follows: progression of known lesions, 14 (66.7%); development of new lesions, 2 (9.5%) and others, 5 (23.8%). Among them, 3 pts achieved stable disease for ≥24 weeks. Subsequent systemic therapy was introduced to 16/21 (76.2%) patients, and 11 received chemotherapy. The median overall survival (OS) from the induction of the 2ndERI was 268.0 days (95% CI 16.1-519.9), and the median OS from the induction of the 1stERI was significantly improved by the 2ndERI (898.0 days vs. 421.0 days; P < 0.001). A significant (P < 0.001) relationship existed between the TTF of the 2ndERI and the OS from the induction of the2ndERI. No significant safety signals were noted.


Re-challenging eribulin is thus considered to be a viable option for patients with ER+HER2-MBC in terms of the efficacy and safety.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Junichiro Watanabe.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.